Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03806309
Title Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)
Acronym TEDOPAM
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.